Tetrazole-substituted arylamides as PX

1. A method for antagonizing a P2X 3 , a P2X 2/3 receptor, or both, by treating the receptor, or receptors, with a compound of formula (I), or a pharmaceutically acceptable salt thereof,

wherein:

R 5 is C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl, C 1-6 alkylsulfanyl-C 1-6 alkyl, C 1-6 alkylsulfonyl-C 1-6 alkyl, amino-C 1-6 alkyl, N—C 1-6 alkyl-amino-C 1-6 alkyl, N,N-di-C 1-6 alkyl-amino-C 1-6 alkyl, C 3-7 cycloalkyl, phenyl, heteroaryl or heterocyclyl-C 1-6 alkyl;

wherein said heteroaryl is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, oxadiazolyl, 3-oxo-2,3-dihydro-isoxazolyl, tetrazolyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-a]pyridinyl, imidazo[4,5-b]pyridinyl, and benzimidazolyl; and wherein said phenyl or heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, halo-C 1-6 alkyl, halo, amino, N—C 1-6 alkyl-amino, and N,N-di-(C 1-6 alkyl)-amino;

wherein said heterocyclyl-C 1-6 alkyl is selected from morpholino-methyl, piperidinyl-methyl, piperazinyl-methyl, thiomorpholinyl-methyl, pyrrolidinyl-methyl, or azetidinyl-methyl and wherein the heterocyclyl portion of said heterocyclyl-C 1-6 alkyl may be optionally substituted once or twice with a substituents independently selected from methyl, methoxy, halo, methanesulfonyl, oxo or acetyl;

R 11 is hydrogen, C 1-6 alkyl, C 1-6 alkyloxy, halo, C 1-6 haloalkyl, hetero-C 1-6 alkyl, C 1-6 alkylsulfonyl or cyano;

R 12 is hydrogen, C 1-6 alkyl, C 1-6 alkyloxy, halo, C 1-6 haloalkyl, hetero-C 1-6 alkyl, C 1-6 alkylsulfonyl or cyano; and,

R 13 is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, hetero-C 1-6 alkyl, C 3-6 -cycloalkyl, C 3-6 cycloalkyl-C 1-6 alkyl or cyano.

2. A method of treating a disease associate with overactivity of P2X 3 and/or P2X 2/3 receptor(s), the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) wherein the disease is a genitourinary disease or urinary tract disease, a respiratory disease, a gastrointestinal disease or a disease is associated with pain,

wherein:

R 3 is C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl, C 1-6 alkylsulfanyl-C 1-6 alkyl, C 1-6 alkylsulfonyl-C 1-6 alkyl, amino-C 1-6 alkyl, N—C 1-6 alkyl-amino-C 1-6 alkyl, N,N-di-C 1-6 alkyl-amino-C 1-6 alkyl, C 3-7 cycloalkyl, phenyl, heteroaryl or heterocyclyl-C 1-6 alkyl;

wherein said heteroaryl is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, imidazolyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, oxadiazolyl, 3-oxo-2,3-dihydro-isoxazolyl, tetrazolyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-a]pyridinyl, imidazo[4,5-b]pyridinyl, and benzimidazolyl; and wherein said phenyl or heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxy-C 1-6 alkyl, halo-C 1-6 alkyl, halo, amino, N—C 1-6 alkyl-amino, and N,N-di-(C 1-6 alkyl)-amino;

wherein said heterocyclyl-C 1-6 alkyl is selected from morpholino-methyl, piperidinyl-methyl, piperazinyl-methyl, thiomorpholinyl-methyl, pyrrolidinyl-methyl, or azetidinyl-menthyl and wherein the heterocyclyl portion of said heterocyclyl-C 1-6 alkyl may be optionally substituted once or twice with a substituents independently selected from methyl, methoxy, halo, methanesulfonyl, oxo or acetyl;

R 33 is hydrogen, C 1-6 alkyl, C 1-6 alkyloxy, halo, C 1-6 haloalkyl, hetero-C 1-6 alkyl, C 1-6 alkylsulfonyl or cyano;

R 32 is hydrogen, C 1-6 alkyl, C 1-6 alkyloxy, halo, C 1-6 haloalkyl, hetero-C 1-6 alkyl, C 1-6 alkylsulfonyl or cyano; and,

R 13 is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, hetero-C 1-6 alkyl, C 3-6 -cycloalkyl, C 3-6 cycloalkyl-C 1-6 alkyl or cyano.

3. The method of claim 2 wherein the disease is a genitourinary disease or urinary tract disease.

4. The method of claim 3 wherein the genitourinary disease or urinary disorder is selected from the group consisting of reduced bladder capacity; frequent micturition; urge incontinence; stress incontinence; bladder hyperreactivity; benign prostatic hypertrophy; prostatitis; detrusor hyperreflexia; urinary frequency; nocturia; urinary urgency; overactive bladder; pelvic hypersensitivity; urethritis; prostatitits; pelvic pain syndrome; prostatodynia; cystitis; and idiophatic bladder hypersensitivity.

5. The method of claim 2 wherein the disease is a respiratory disease.

6. The method of claim 5 wherein the respiratory disease is chronic obstructive pulmonary disorder (COPD), asthma, or bronchospasm.

7. The method of claim 2 wherein the disease is a gastrointestinal disease.

8. The method of claim 7 wherein the gastrointestinal disease is selected from the group consisting of Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic and pain associated with gastrointestinal distension.

9. The method of claim 2 wherein the disease associated with overactivity of P2X3 and/or P2X2/3 receptor(s) is the disease associated with pain.

10. A method of claim 9 wherein the disease associated with pain is selected from the group consisting of inflammatory pain; surgical pain; visceral pain; dental pain; premenstrual pain; central pain; pain due to burns; migraine or cluster headaches; nerve injury; neuritis; neuralgias; poisoning; ischemic injury; interstitial cystitis; cancer pain; viral, parasitic or bacterial infection; post-traumatic injury; and pain associated with irritable bowel syndrome.